<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34913414</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Concanavalin A promotes angiogenesis and proliferation in endothelial cells through the Akt/ERK/Cyclin D1 axis.</ArticleTitle>
        <Pagination>
          <StartPage>65</StartPage>
          <EndPage>74</EndPage>
          <MedlinePgn>65-74</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2021.2013259</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Concanavalin A (Con A) exhibited multiple roles in cancer cells. However, the role of Con A in endothelial cells was not reported.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our present study investigated the potential angiogenic role of Con A in endothelial cells and ischaemic hind-limb mice.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Human umbilical vein endothelial cells and Ea.hy926 cells were employed to determine the effect of Con A (0.3, 1, and 3 μg/mL) or vehicle on angiogenesis and cell proliferation with tube formation, ELISA, flow cytometry, EdU, and western blot. Hind-limb ischaemic mice were conducted to determine the pro-angiogenic effect of Con A (10 mg/kg) for 7 days.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Con A promoted tube formation to about three-fold higher than the control group and increased the secretion of VEGFa, PDGFaa, and bFGF in the medium. The cell viability was promoted to 1.3-fold by Con A 3 μg/mL, and cell cycle progression of G0G1 phase was decreased from 77% in the vehicle group to 70% in Con A 3 μg/mL, G2M was promoted from 15 to 19%, and S-phase was from 7 to 10%. Con A significantly stimulated phosphorylation of Akt and ERK1/2 and expression of cyclin D1 and decreased the expression of p27. These effects of Con A were antagonised by the PI3K inhibitor LY294002 (10 μM) and MEK pathway antagonist PD98059 (10 μM). Moreover, Con A (10 mg/kg) exhibited a repair effect in ischaemic hind-limb mice.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">This study will provide a new option for treating ischaemic disease by local injection with Con A.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jing-Zhou</ForeName>
            <Initials>JZ</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiao-Xia</ForeName>
            <Initials>XX</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Wei-Yin</ForeName>
            <Initials>WY</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiang</LastName>
            <ForeName>Hai-Feng</ForeName>
            <Initials>HF</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Guo-Sheng</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043925">Angiogenesis Inducing Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>11028-71-0</RegistryNumber>
          <NameOfSubstance UI="D003208">Concanavalin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>136601-57-5</RegistryNumber>
          <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31M2U1DVID</RegistryNumber>
          <NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SJE1IO5E3I</RegistryNumber>
          <NameOfSubstance UI="C093973">2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D043925" MajorTopicYN="N">Angiogenesis Inducing Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003208" MajorTopicYN="N">Concanavalin A</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006614" MajorTopicYN="N">Hindlimb</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018919" MajorTopicYN="N">Neovascularization, Physiologic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cell proliferation</Keyword>
        <Keyword MajorTopicYN="N">HUVECs</Keyword>
        <Keyword MajorTopicYN="N">PDGF</Keyword>
        <Keyword MajorTopicYN="N">VEGF</Keyword>
        <Keyword MajorTopicYN="N">bFGF</Keyword>
        <Keyword MajorTopicYN="N">cell cycling</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>8</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34913414</ArticleId>
        <ArticleId IdType="pmc">PMC8725916</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2021.2013259</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Arsenijevic D, Stojanovic B, Milovanovic J, Arsenijevic A, Simic M, Pergal M, Kodranov I, Cvetkovic O, Vojvodic D, Ristanovic E, et al. . 
2021. Hepatoprotective effect of mixture of dipropyl polysulfides in concanavalin A-induced hepatitis. Nutrients. 13(3):1022–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8004208</ArticleId>
            <ArticleId IdType="pubmed">33809904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballerstadt R, Evans C, McNichols R, Gowda A.. 
2006. Concanavalin A for in vivo glucose sensing: a biotoxicity review. Biosens Bioelectron. 22(2):275–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16488598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baudin B, Bruneel A, Bosselut N, Vaubourdolle M.. 
2007. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc. 2(3):481–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17406610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas MH, Hasegawa HH, Rahman MA, Huang P, Mon NN, Ruhul Amin AR, Senga T, Kannagi R, Hamaguchi M.. 
2006. SHP-2-Erk signaling regulates concanavalin A-dependent production of TIMP-2. Biochem Biophys Res Commun. 348(3):1145–1149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16904070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blaes N, Girolami JP.. 
2013. Targeting the 'Janus face' of the B2-bradykinin receptor. Expert Opin Ther Targets. 17(10):1145–1166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23957374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Che H, Li G, Sun HY, Xiao GS, Wang Y, Li GR.. 
2015. Roles of store-operated Ca2+ channels in regulating cell cycling and migration of human cardiac c-kit + progenitor cells. Am J Physiol Heart Circ Physiol. 309(10):H1772–H1781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26453325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CH, Jiang W, Via DP, Luo S, Li TR, Lee YT, Henry PD.. 
2000. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation. 101(2):171–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10637205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Karamariti E, Hong X, Deng J, Wu Y, Gu W, Simpson R, Wong MM, Yu B, Hu Y, et al. . 
2019. DKK3 (Dikkopf-3) Transdifferentiates fibroblasts into functional endothelial cells-brief report. Arterioscler Thromb Vasc Biol. 39(4):765–773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6445366</ArticleId>
            <ArticleId IdType="pubmed">30816803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deanfield JE, Halcox JP, Rabelink TJ.. 
2007. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 115(10):1285–1295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17353456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elshal M, Abu-Elsaad N, El-Karef A, Ibrahim T.. 
2021. Etanercept attenuates immune-mediated hepatitis induced by concanavalin A via differential regulation of the key effector cytokines of CD4+ T cells. Life Sci. 277:119618–119619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34004252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flammer AJ, Gossl M, Li J, Matsuo Y, Reriani M, Loeffler D, Simari RD, Lerman LO, Khosla S, Lerman A.. 
2012. Patients with an HbA1c in the prediabetic and diabetic range have higher numbers of circulating cells with osteogenic and endothelial progenitor cell markers. J Clin Endocrinol Metab. 97(12):4761–4768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3513527</ArticleId>
            <ArticleId IdType="pubmed">23015657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu C, Li B, Sun Y, Ma G, Yao Y.. 
2015. Bradykinin inhibits oxidative stress-induced senescence of endothelial progenitor cells through the B2R/AKT/RB and B2R/EGFR/RB signal pathways. Oncotarget. 6(28):24675–24689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4694787</ArticleId>
            <ArticleId IdType="pubmed">26360782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G.. 
1995. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology. 21(1):190–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7806154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong WG, Lin JL, Niu QX, Wang HM, Zhou YC, Chen SY, Liang GW.. 
2015. Paeoniflorin diminishes ConA-induced IL-8 production in primary human hepatic sinusoidal endothelial cells in the involvement of ERK1/2 and Akt phosphorylation. Int J Biochem Cell Biol. 62:93–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25748730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibrahim SRM, Sirwi A, Eid BG, Mohamed SGA, Mohamed GA.. 
2021. Summary of natural products ameliorate concanavalin A-induced liver injury: structures, sources, pharmacological effects, and mechanisms of action. Plants. 10(2):228–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7910830</ArticleId>
            <ArticleId IdType="pubmed">33503905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kar F, Kacar S, Hacioglu C, Kanbak G, Sahinturk V.. 
2021. Concanavalin A induces apoptosis in a dose-dependent manner by modulating thiol/disulfide homeostasis in C6 glioblastoma cells. J Biochem Mol Toxicol. 35(5):e22742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33604990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan HA, Munir T, Khan JA, Shafia Tehseen Gul AH, Ahmad MZ, Aslam MA, Umar MN, Arshad MI.. 
2021. IL-33 ameliorates liver injury and inflammation in Poly I:C and Concanavalin-A induced acute hepatitis. Microb Pathog. 150:104716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33383149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni GV, McCulloch CA.. 
1995. Concanavalin A induced apoptosis in fibroblasts: the role of cell surface carbohydrates in lectin mediated cytotoxicity. J Cell Physiol. 165(1):119–133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7559793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li CY, Xu HL, Liu B, Bao JK.. 
2010. Concanavalin A, from an old protein to novel candidate anti-neoplastic drug. Curr Mol Pharmacol. 3(3):123–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20533895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Che H, Wu WY, Jie LJ, Xiao GS, Wang Y, Li GR.. 
2018. Bradykinin-mediated Ca2+ signalling regulates cell growth and mobility in human cardiac c-Kit+ progenitor cells. J Cell Mol Med. 22(10):4688–4699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6156395</ArticleId>
            <ArticleId IdType="pubmed">30117680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Kong D, Qin Y, Wang H, Hu Y, Zhao Y, Hao J, Qin H, Yu D, Zhu Y, et al. . 
2021. IL-37 overexpression enhances the therapeutic effect of endometrial regenerative cells in concanavalin A-induced hepatitis. Cytotherapy. 23(7):617–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33593687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Wang Y, Li GR.. 
2017. Bradykinin regulates cell growth and migration in cultured human cardiac c-Kit+ progenitor cells. Oncotarget. 8(7):10822–10835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5355226</ArticleId>
            <ArticleId IdType="pubmed">28099911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li WW, Yu JY, Xu HL, Bao JK.. 
2011. Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun. 414(2):282–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21951850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Gong L, Weng L, Pan X, Liu C, Li M.. 
2021. Interleukin-39 exacerbates concanavalin A-induced liver injury. Immunopharmacol Immunotoxicol. 43(1):94–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33412981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, Bian HJ, Bao JK.. 
2010. Plant lectins: potential antineoplastic drugs from bench to clinic. Cancer Lett. 287(1):1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19487073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, Li CY, Bian HJ, Min MW, Chen LF, Bao JK.. 
2009. Antiproliferative activity and apoptosis-inducing mechanism of Concanavalin A on human melanoma A375 cells. Arch Biochem Biophys. 482(1–2):1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19111670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo ML, Liu XP, Wang F, Liu XX, Liu WF, Wu D, Tao H, Wang RL, Zhao Y, Zhu JW, et al. . 
2018. Conditioned medium from human umbilical vein endothelial cells promotes proliferation, migration, invasion and angiogenesis of adipose derived stem cells. Curr Med Sci. 38(1):124–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30074161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMillan PN, Ferayorni LS, Gerhardt CO, Jauregui HO.. 
1984. Light and electron microscope analysis of lectin binding to adult rat liver in situ. Lab Invest. 50(4):408–420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6368972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Wang J, Yuan Y, Cao G, Fan S, Gao C, Wang L, Li Z, Wu X, Wu Z, et al. . 
2017. γδ T cells are indispensable for interleukin-23-mediated protection against concanavalin A-induced hepatitis in hepatitis B virus transgenic mice. Immunology. 151(1):43–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5382349</ArticleId>
            <ArticleId IdType="pubmed">28092402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H.. 
1992. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med. 175(1):91–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2119077</ArticleId>
            <ArticleId IdType="pubmed">1730929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicoletti NF, Erig TC, Zanin RF, Pereira TC, Bogo MR, Campos MM, Morrone FB.. 
2014. Mechanisms involved in kinin-induced glioma cells proliferation: the role of ERK1/2 and PI3K/Akt pathways. J Neurooncol. 120(2):235–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25056222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peschke T, Wollweber L, Gabert A, Augsten K, Stracke R.. 
1990. Effect of different fixatives on Con A surface receptors of mouse peritoneal macrophages. Histochemistry. 93(4):443–446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2323960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pink JR, Hoessli D, Tartakoff A, Hooghe R.. 
1983. Characterisation of concanavalin A-binding glycoproteins from mouse splenic leukocytes by two-dimensional electrophoresis: preferential binding of incompletely glycosylated forms of H-2 antigen to the lectin. Mol Immunol. 20(4):491–497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6865960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pober JS, Min W, Bradley JR.. 
2009. Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol. 4:71–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18754744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruhul Amin AR, Oo ML, Senga T, Suzuki N, Feng GS, Hamaguchi M.. 
2003. SH2 domain containing protein tyrosine phosphatase 2 regulates concanavalin A-dependent secretion and activation of matrix metalloproteinase 2 via the extracellular signal-regulated kinase and p38 pathways. Cancer Res. 63(19):6334–6339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14559821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sang XX, Wang RL, Zhang CE, Liu SJ, Shen HH, Guo YM, Zhang YM, Niu M, Wang JB, Bai ZF, et al. . 
2017. Sophocarpine protects mice from con A-induced hepatitis via inhibition of the IFN-Gamma/STAT1 Pathway. Front Pharmacol. 8:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5359249</ArticleId>
            <ArticleId IdType="pubmed">28377718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki N, Toyoda M.. 
2013. Glycoconjugates and related molecules in human vascular endothelial cells. Int J Vasc Med. 2013:963596–963510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3793293</ArticleId>
            <ArticleId IdType="pubmed">24171112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaumburg-Lever G.
1990. Ultrastructural localization of lectin-binding sites in normal skin. J Invest Dermatol. 94(4):465–470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2313119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H, Hristov M, et al. . 
2014. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 20(4):368–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4398028</ArticleId>
            <ArticleId IdType="pubmed">24584117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sina A, Proulx-Bonneau S, Roy A, Poliquin L, Cao J, Annabi B.. 
2010. The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway. J Cell Commun Signal. 4(1):31–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2821472</ArticleId>
            <ArticleId IdType="pubmed">20195390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Singh H, Jagavelu K, Wahajuddin M, Hanif K.. 
2017. Fatty acid synthase modulates proliferation, metabolic functions and angiogenesis in hypoxic pulmonary artery endothelial cells. Eur J Pharmacol. 815:462–469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28974347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong Q, Zheng L, Li B, Wang D, Huang C, Matuschak GM, Li D.. 
2006. Hypoxia-induced mitogenic factor enhances angiogenesis by promoting proliferation and migration of endothelial cells. Exp Cell Res. 312(18):3559–3569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16982054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velasquez EV, Rios M, Ortiz ME, Lizama C, Nunez E, Abramovich D, Orge F, Oliva B, Orellana R, Villalon M, et al. . 
2013. Concanavalin-A induces granulosa cell death and inhibits FSH-mediated follicular growth and ovarian maturation in female rats. Endocrinology. 154(5):1885–1896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23515285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu P, Zhang Z, Li S, Wen X, Quan W, Tian Q, Chen J, Zhang J, Jiang R.. 
2016. Progesterone modulates endothelial progenitor cell (EPC) viability through the CXCL12/CXCR4/PI3K/Akt signalling pathway. Cell Prolif. 49(1):48–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6495665</ArticleId>
            <ArticleId IdType="pubmed">26818151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Li Q, Zhou C, Zhao Y, Li R, Zhang Y.. 
2020. Demethyleneberberine attenuates concanavalin A-induced autoimmune hepatitis in mice through inhibition of NF-κB and MAPK signaling. Int Immunopharmacol. 80:106137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31931366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YY, Li G, Che H, Sun HY, Xiao GS, Wang Y, Li GR.. 
2015. Effects of BKCa and Kir2.1 channels on cell cycling progression and migration in human cardiac c-kit+ progenitor cells. PLOS One. 10(9):e0138581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4577111</ArticleId>
            <ArticleId IdType="pubmed">26390131</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
